Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.04, Zacks reports. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative return on equity of 82.92% and a negative net margin of 102.34%.

Cellectis Stock Up 5.6%

Shares of NASDAQ CLLS traded up $0.15 during trading hours on Friday, hitting $2.84. The stock had a trading volume of 24,095 shares, compared to its average volume of 16,107. The company has a market capitalization of $284.97 million, a P/E ratio of -4.37 and a beta of 2.91. The firm’s 50-day moving average price is $2.95 and its two-hundred day moving average price is $3.48. Cellectis has a 52 week low of $2.35 and a 52 week high of $5.48. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52.

Analyst Ratings Changes

A number of research firms have recently issued reports on CLLS. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Citizens Jmp reissued a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Barclays began coverage on shares of Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cellectis has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Institutional Trading of Cellectis

A number of institutional investors have recently added to or reduced their stakes in CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Cellectis during the 3rd quarter valued at $72,000. Citadel Advisors LLC acquired a new stake in shares of Cellectis in the 3rd quarter valued at $633,000. Finally, Millennium Management LLC lifted its stake in shares of Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.